3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Other neoplasm
1
Conditions
Keratosis, Actinic
2
Keratosis
2
Precancerous Conditions
1
Neoplasms
1
Interventions
pembrolizumab
69
Nivolumab
57
Ipilimumab
36
Specimen Handling
32
Magnetic Resonance Spectroscopy
25
Cyclophosphamide
22
Biopsy
18
cemiplimab
14
fludarabine
13
relatlimab
11
binimetinib
11
Opdualag
11
CTLA-4 Antigen
11
trametinib
10
fludarabine phosphate
10
Radiosurgery
10
avelumab
9
lifileucel
8
dabrafenib
8
Radiotherapy
8
atezolizumab
7
aldesleukin
7
Paclitaxel
7
Blood Specimen Collection
7
encorafenib
6
X-Rays
6
Standard of Care
6
Interleukin-2
6
Immunoglobulin G
6
HhAntag691
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
tirbanibulin
×
Dermatologic
×
90 days
×
Clear all
NCT07273656
2026-05-22
TIRBACRYO
University Hospital, Lille
Phase 3
Not yet recruiting
59 enrolled
NCT06135415
2026-03-25
TirbAKare
Almirall, S.A.
Phase 3
Completed
280 enrolled